Rhenman & Partners Asset Management AB lessened its position in shares of Glaukos Corp (NYSE:GKOS) by 14.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 240,579 shares of the medical instruments supplier’s stock after selling 40,700 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Glaukos were worth $13,513,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of GKOS. SG Americas Securities LLC acquired a new position in shares of Glaukos during the 4th quarter worth about $2,555,000. Rhumbline Advisers increased its stake in shares of Glaukos by 49.5% during the 4th quarter. Rhumbline Advisers now owns 44,801 shares of the medical instruments supplier’s stock worth $2,516,000 after purchasing an additional 14,828 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new position in Glaukos in the 4th quarter valued at about $31,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Glaukos by 24.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,583 shares of the medical instruments supplier’s stock valued at $145,000 after buying an additional 508 shares during the last quarter. Finally, Strs Ohio acquired a new position in Glaukos in the 4th quarter valued at about $78,000.
In other Glaukos news, Director William J. Phd Link sold 41,500 shares of the stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $57.62, for a total transaction of $2,391,230.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Joseph E. Gilliam sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 28th. The stock was sold at an average price of $60.03, for a total transaction of $300,150.00. Following the sale, the chief financial officer now directly owns 86,117 shares of the company’s stock, valued at approximately $5,169,603.51. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 63,075 shares of company stock worth $3,653,652. Company insiders own 11.60% of the company’s stock.
Separately, Zacks Investment Research upgraded shares of Glaukos from a “sell” rating to a “hold” rating in a research note on Tuesday, November 13th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $58.20.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://weekherald.com/2019/02/11/rhenman-partners-asset-management-ab-lowers-holdings-in-glaukos-corp-gkos.html.
Glaukos Company Profile
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.
Featured Story: Discover Your Risk Tolerance
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corp (NYSE:GKOS).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.